Altre lingue Gan & Lee Pharmaceuticals.

Azioni

603087

CNE100003ZH1

Prezzo di chiusura Shanghai S.E. Altri mercati azionari 00:00:00 25/06/2024			Variaz. 5gg	Var. 1 gen.
47,83 ^CNY	-2,71%		+0,17%	-9,15%

24/04	Gan & Lee Pharmaceuticals. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
24/04	Gan & Lee Pharmaceuticals. riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions	22/06
Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association's 84th Scientific Sessions	18/06
Gan & Lee Pharmaceuticals.(SHSE:603087) added to SSE 180 Index	17/06
Gan & Lee Pharmaceuticals.(SHSE:603087) added to Shanghai Stock Exchange 180 Value Index	17/06
Gan & Lee Pharmaceuticals Gets Mexico's Drug Registration Approval for Insulin Glargine Injection	24/05
Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 31, 2024	24/04
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Full Year Ended December 31, 2023	24/04
Gan & Lee Pharma's Insulin Product Gets Registration Approval in Bolivia	26/01
Gan & Lee Pharmaceuticals Administers First Subject in Phase II Study of GZR101 Diabetes Drug	12/12
Gan & Lee Pharmaceuticals' Unit Gets Nod to Test GZR18 Tablets	04/12
Gan & Lee Pharmaceuticals. announced that it has received CNY 773.151876 million in funding	10/11
Type 1 Diabetes Pipeline\| Clinical Trials and Key Companies - Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma	09/11
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2023	30/10/23
Gan & Lee Pharma’s Insulin Analogs Gain EU Regulatory Approval	12/10/23
Gan & Lee Pharmaceuticals.(XSSC:603087) added to S&P Global BMI Index	18/09/23
Gan & Lee Pharmaceuticals.(XSSC:603087) added to FTSE All-World Index	18/09/23
Gan & Lee Pharma Advances Trial of New Insulin Product	13/09/23
Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 2023	18/08/23
Gan & Lee Pharmaceuticals Gets Nod to Trial GLR1023 Injection	20/07/23
Gan & Lee Pharmaceuticals Gets Regulatory Nod for Private Placement	20/06/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Gan & Lee Pharmaceuticals.

Azioni

603087

CNE100003ZH1

Altre lingue

Filtri